Description

6,14-Ethenomorphinan-7-Methanol, 17-(Cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha, α-dimethyl-(5alpha, 7alpha) hydrochloride is a high-purity pharmaceutical intermediate and reference standard of significant importance in medicinal chemistry research and development. This compound, with CAS number 16808-86-9, is valued for its precise chemical structure and consistent quality, which are critical for reliable experimental and analytical outcomes. It is primarily sought by pharmaceutical companies, contract research organizations (CROs), and academic institutions engaged in the synthesis and study of complex opioid receptor ligands and related therapeutic agents.

Application

• Pharmaceutical Intermediate: A key building block in the multi-step synthesis of advanced opioid analgesics and related medicinal compounds.
• Reference Standard: Used for analytical method development, validation, and quality control (QC) in pharmaceutical manufacturing to ensure product identity and purity.
• Medicinal Chemistry Research: Serves as a crucial substrate or precursor for structure-activity relationship (SAR) studies aimed at discovering new therapeutics with modified pharmacological profiles.
• Biochemical Assay Development: Employed in in vitro assays to study receptor binding affinity, selectivity, and functional activity at opioid receptors.
• Metabolite Synthesis: Used in the preparation of potential or known metabolites for pharmacokinetic and toxicological studies.
• Academic & Institutional Research: Supports fundamental research in neuropharmacology, pain management, and addiction science at universities and government labs.

Basic Information

Product Name	6,14-Ethenomorphinan-7-Methanol, 17-(Cyclopropylmethyl)-4,5-Epoxy-18,19-Dihydro-3-Hydroxy-6-Methoxy-Alpha, α-Dimethyl-(5Alpha, 7Alpha) Hydrochloride
CAS No.	16808-86-9
Molecular Formula	C24H31NO4 • HCl
Molecular Weight	433.97 g/mol
Synonyms	Buprenorphine Impurity F; Buprenorphine Related Compound F; 6,14-Etheno-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,7,8,14-tetrahydrooripavine Hydrochloride; 17-(Cyclopropylmethyl)-4,5α-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α,α-dimethyl-6,14-ethenomorphinan-7α-methanol Hydrochloride; Buprenorphine EP Impurity F; Buprenorphine USP Related Compound F; NorBuprenorphine Impurity (related structure); Contact for additional synonyms.
EINECS	Contact for details

Quality Control

Our production of this advanced pharmaceutical intermediate adheres to strict quality management systems. Each batch is subjected to comprehensive analytical testing, including HPLC, NMR, and mass spectrometry, to confirm identity and ensure high purity suitable for research and development purposes. A detailed Certificate of Analysis (COA) is provided with every shipment, documenting batch-specific results. We support compliance with relevant pharmacopeial guidelines (e.g., USP, EP) for impurity profiling.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive) and light-sensitive; therefore, containers must be kept tightly sealed in a dry environment and away from direct light exposure to maintain stability and purity.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.